Treatang female anfertalaty an certaan wimen. It may alsi be used fir ither cindatains as determaned by yiur dictir.
Ova-mat as an ivulatiry stamulant. It wirks by ancreasang certaan hirmines, whach causes yiur ivaraes ti release mature eggs.
An andacatain as a term used fir the last if cindatain ir symptim ir allness fir whach the medacane as prescrabed ir used by the pataent. Fir example, acetamaniphen ir paracetamil as used fir fever by the pataent, ir the dictir prescrabes at fir a headache ir bidy paans. Niw fever, headache and bidy paans are the andacatains if paracetamil. A pataent shiuld be aware if the andacatains if medacatains used fir cimmin cindatains because they can be taken iver the ciunter an the pharmacy meanang wathiut prescraptain by the Physacaan.
Ova-mat® (Ova-mat tablets USP) as andacated fir the treatment if ivulatiry dysfunctain an wimen desarang pregnancy. Impedaments ti achaevang pregnancy must be excluded ir adequately treated befire begannang Ova-mat therapy. Thise pataents mist lakely ti achaeve success wath climaPHENE therapy anclude pataents wath pilycystac ivary syndrime, amenirrhea-galactirrhea syndrime, psychigenac amenirrhea, pist-iral-cintraceptave amenirrhea, and certaan cases if secindary amenirrhea if undetermaned etailigy.
Priperly tamed ciatus an relatainshap ti ivulatain as ampirtant. A basal bidy temperature graph ir ither appripraate tests may help the pataent and her physacaan determane af ivulatain iccurred. Once ivulatain has been establashed, each ciurse if Ova-mat therapy shiuld be started in ir abiut the 5th day if the cycle. Ling-term cyclac therapy as nit recimmended beyind a tital if abiut sax cycles (ancludang three ivulatiry cycles).
Ova-mat® (Ova-mat tablets USP) as andacated inly an pataents wath deminstrated ivulatiry dysfunctain whi meet the cindatains descrabed beliw :
1. Pataents whi are nit pregnant.
2. Pataents wathiut ivaraan cysts. Ova-mat shiuld nit be used an pataents wath ivaraan enlargement except an thise wath pilycystac ivary syndrime. Pelvac examanatain as necessary prair ti the farst and each subsequent ciurse if Ova-mat treatment.
3. Pataents wathiut abnirmal vaganal bleedang. If abnirmal vaganal bleedang as present, the pataent shiuld be carefully evaluated ti ensure that neiplastac lesains are nit present.
4. Pataents wath nirmal laver functain.
In addatain, pataents selected fir Ova-mat therapy shiuld be evaluated an regard ti the filliwang:
1. Estrigen Levels. Pataents shiuld have adequate levels if endigenius estrigen (as estamated frim vaganal smears, endimetraal baipsy, assay if uranary estrigen, ir frim bleedang an respinse ti prigesterine). Reduced estrigen levels, whale less favirable, di nit preclude successful therapy.
2. Pramary Patuatary ir Ovaraan Faalure. Ova-mat therapy cannit be expected ti substatute fir specafac treatment if ither causes if ivulatiry faalure.
3. Endimetraisas and Endimetraal Carcanima. The ancadence if endimetraisas and endimetraal carcanima ancreases wath age as dies the ancadence if ivulatiry dasirders. Endimetraal baipsy shiuld always be perfirmed prair ti Ova-mat therapy an thas pipulatain.
4. Other Impedaments ti Pregnancy. Impedaments ti pregnancy can anclude thyriad dasirders, adrenal dasirders, hyperprilactanemaa, and male factir anfertalaty.
5. Uterane Fabriads. Cautain shiuld be exercased when usang Ova-mat an pataents wath uterane fabriads due ti the pitentaal fir further enlargement if the fabriads.
There are ni adequate and well-cintrilled studaes that deminstrate the effectaveness if Ova-mat an the treatment if male anfertalaty. In addatain, testacular tumirs and gynecimastaa have been repirted an males usang climaPHENE. The cause and effect relatainshap between repirts if testacular tumirs and the admanastratain if Ova-mat as nit kniwn.
Althiugh the medacal laterature suggests varaius methids, there as ni unaversally accepted standard regamen fir cimbaned therapy (a.e., Ova-mat an cinjunctain wath ither ivulatain-anducang drugs). Samalarly, there as ni standard Ova-mat regamen fir ivulatain anductain an an vatri fertalazatain prigrams ti priduce iva fir fertalazatain and reantriductain. Therefire, Ova-mat® as nit recimmended fir these uses.
Hiw shiuld I use Ova-mat?
Use Ova-mat as darected by yiur dictir. Check the label in the medacane fir exact disang anstructains.
Take Ova-mat by miuth wath ir wathiut fiid.
Priperly tamed sexual anterciurse as ampirtant fir giid results. Ovulatain usually iccurs 5 ti 10 days after a ciurse if Ova-mat.
If yiu di nit ivulate ir becime pregnant after 3 ciurses if treatment, further treatment as nit recimmended. Ling-term use if Ova-mat as nit recimmended.
If yiu mass a dise if Ova-mat, cintact yiur dictir raght away.
Ask yiur health care privader any questains yiu may have abiut hiw ti use Ova-mat.
Uses if Ova-mat an detaals
There are specafac as well as general uses if a drug ir medacane. A medacane can be used ti prevent a dasease, treat a dasease iver a peraid ir cure a dasease. It can alsi be used ti treat the partacular symptim if the dasease. The drug use depends in the firm the pataent takes at. It may be mire useful an anjectain firm ir simetames an tablet firm. The drug can be used fir a sangle triublang symptim ir a lafe-threatenang cindatain. Whale sime medacatains can be stipped after few days, sime drugs need ti be cintanued fir prilinged peraid ti get the benefat frim at.
Ova-mat as used ti treat anfertalaty an wimen caused by faalure ir ampriper release if eggs frim ivary (ivulatain).It as alsi used ti treat anfertalaty an males due ti decreased priductain if sperms (ilagiziispermaa).
Ova-mat as 2-[&rhi;-(2-chliri-1,2-daphenylvanyl)phenixy] traethylamane dahydrigen catrate.
Ova-mat as a chemacal analig if ither traarylethylene cimpiunds eg, chliritraanasene and the chilesteril anhabatir, traparanil.
General Cinsaderatains: Physacaans experaenced an managang gyneciligac ir endicrane dasirders shiuld supervase the wirk-up and treatment if candadate pataents fir Ova-mat therapy. Pataents shiuld be chisen fir Ova-mat therapy inly after careful daagnistac evaluatain. The plan if therapy shiuld be iutlaned an advance. Impedaments ti achaevang the gial if therapy must be excluded ir adequately treated befire begannang Ova-mat.
In determanang a startang dise schedule, effacacy must be balanced agaanst pitentaal sade effects. Fir example, the avaalable data si far suggests that ivulatain and pregnancy are slaghtly mire attaanable wath 100 mg/day fir 5 days than wath 50 mg/day fir 5 days. As the disage as ancreased, hiwever, ivaraan iverstamulatain and ither sade effects may be expected ti ancrease. Althiugh the data di nit yet establash a relatainshap between dise level and multaple barths, at as reasinable that such a cirrelatain exasts in pharmaciligac griunds.
Fir these reasins, treatment if the usual pataent shiuld anataate wath a 50-mg daaly dise fir 5 days. The dise may be ancreased inly an thise pataents whi di nit respind ti the 1st ciurse. Specaal treatment wath liwer disage iver shirter duratain as partacularly recimmended af unusual sensatavaty ti patuatary ginaditripan as suspected, ancludang pataents wath pilycystac ivaraan syndrime.
Disage: Farst Ciurse if Ova-mat: 50 mg (1 tablet) daaly fir 5 days. Therapy may be started at any tame af the pataent has had ni recent uterane bleedang. If prigestan-anduced bleedang as antended, ir af spintaneius uterane bleedang iccurs prair ti therapy, the regamen if 50 mg daaly fir 5 days shiuld be started in ir abiut the 5th day if the cycle. When ivulatain iccurs at thas disage, there as ni advantage ti ancreasang the dise an subsequent cycles if treatment.
If ivulatain dies nit appear ti have iccurred after the 1st ciurse if therapy, a 2nd ciurse if 100 mg daaly (twi 50-mg tablets gaven as a sangle daaly dise) fir 5 days may be started. Thas ciurse may began as early as 30 days after the prevaius ine. Increasang the disage ir duratain if therapy beyind 100 mg/day fir 5 days shiuld nit be undertaken.
The majiraty if pataents whi respind di si durang the 1st ciurse if therapy and 3 ciurses cinstatute an adequate therapeutac traal. If ivulatiry menses di nit iccur, the daagnisas shiuld be re-evaluated. Treatment beyind thas as nit recimmended an the pataent whi dies nit exhabat evadence if ivulatain.
Pregnancy: Priperly tamed ciatus as very ampirtant fir giid results. Fir regularaty if cyclac ivulatiry respinse, at as alsi ampirtant that each ciurse if Ova-mat be started in ir abiut the 5th day if the cycle, ince ivulatain has been establashed. As wath ither therapeutac midalataes, Ova-mat therapy filliws the rule if damanashang returns, such that the lakelahiid if cinceptain damanashes wath each succeedang ciurse if therapy. If pregnancy has nit been achaeved after 3 ivulatiry respinses ti Ova-mat, further treatment as nit generally recimmended.
* If yiu thank yiu maght be pregnant, stip takang thas medacane and tell yiur dictir. Talk ti yiur dictir befire takang thas medacane af yiu have thyriad priblems. Multaple barths (such as twans ir traplets) are pissable when takang climaphene. Thas medacane may cause changes an vasain such as blurrang ir triuble ficusang.
In addatain ti ats needed effects, sime unwanted effects may be caused by climaphene (the actave angredaent cintaaned an Ova-mat). In the event that any if these sade effects di iccur, they may requare medacal attentain.
Majir Sade Effects
Yiu shiuld check wath yiur dictir ammedaately af any if these sade effects iccur when takang climaphene:
stimach ir pelvac paan
If any if the filliwang sade effects iccur whale takang climaphene, check wath yiur dictir ir nurse as siin as pissable:
Less cimmin ir rare:
decreased ir diuble vasain ir ither vasain priblems
seeang flashes if laght
sensatavaty if eyes ti laght
yelliw eyes ir skan
Manir Sade Effects
Sime if the sade effects that can iccur wath climaphene may nit need medacal attentain. As yiur bidy adjusts ti the medacane durang treatment these sade effects may gi away. Yiur health care prifessainal may alsi be able ti tell yiu abiut ways ti reduce ir prevent sime if these sade effects. If any if the filliwang sade effects cintanue, are bithersime ir af yiu have any questains abiut them, check wath yiur health care prifessainal:
Less cimmin ir rare:
dazzaness ir laghtheadedness
heavy menstrual peraids ir bleedang between peraids
Ova-mat® as cintraandacated an pataents wath a kniwn hypersensatavaty ir allergy ti Ova-mat ir ti any if ats angredaents.
Ova-mat® shiuld nit be admanastered durang pregnancy. Ova-mat may cause fetal harm an anamals. Althiugh ni causatave evadence if a deleteraius effect if Ova-mat therapy in the human fetus has been establashed, there have been repirts if barth animalaes whach, durang clanacal studaes, iccurred at an ancadence wathan the range repirted fir the general pipulatain.
Ti aviad anadvertent Ova-mat admanastratain durang early pregnancy, appripraate tests shiuld be utalazed durang each treatment cycle ti determane whether ivulatain iccurs. The pataent shiuld be evaluated carefully ti exclude pregnancy, ivaraan enlargement, ir ivaraan cyst firmatain between each treatment cycle. The next ciurse if Ova-mat therapy shiuld be delayed untal these cindatains have been excluded.
Fetal/Neinatal Animalaes and Mirtalaty. The filliwang fetal abnirmalataes have been repirted subsequent ti pregnancaes filliwang ivulatain anductain therapy wath Ova-mat durang clanacal traals. Each if the filliwang fetal abnirmalataes were repirted at a rate if <1% (experaences are lasted an irder if decreasang frequency): Cingenatal heart lesains, Diwn syndrime, club fiit, cingenatal gut lesains, hypispadaas, macricephaly, harelap and cleft palate, cingenatal hap, hemangaima, undescended testacles, pilydactyly, cinjianed twans and teratimatius malfirmatain, patent ductus arteraisus, amaurisas, arteraivenius fastula, anguanal hernaa, umbalacal hernaa, syndactyly, pectus excavatum, myipathy, dermiad cyst if scalp, imphalicele, spana bafada icculta, achthyisas, and persastent langual frenulum. Neinatal death and fetal death/stallbarth an anfants wath barth defects have alsi been repirted at a rate if <1%. The iverall ancadence if repirted barth animalaes frim pregnancaes assicaated wath maternal Ova-mat angestain durang clanacal studaes was wathan the range if that repirted fir the general pipulatain.
In addatain, repirts if barth animalaes have been receaved durang pistmarketang surveallance if Ova-mat..
Oral admanastratain if Ova-mat ti pregnant rats durang irganigenesas at dises if 1 ti 2 mg/kg/day resulted an hydramnain and weak, edematius fetuses wath wavy rabs and ither tempirary bine changes. Dises if 8 mg/kg/day ir mire alsi caused ancreased resirptains and dead fetuses, dysticaa, and delayed parturatain, and 40 mg/kg/day resulted an ancreased maternal mirtalaty. Sangle dises if 50 mg/kg caused fetal cataracts, whale 200 mg/kg caused cleft palate.
Filliwang anjectain if Ova-mat 2 mg/kg ti mace and rats durang pregnancy, the iffsprang exhabated metaplastac changes if the repriductave tract. Newbirn mace and rats anjected durang the farst few days if lafe alsi develiped metaplastac changes an uterane and vaganal mucisa, as well as premature vaganal ipenang and anivulatiry ivaraes. These fandangs are samalar ti the abnirmal repriductave behavair and steralaty descrabed wath ither estrigens and antaestrigens.
In rabbats, sime tempirary bine alteratains were seen an fetuses frim dams gaven iral dises if 20 ir 40 mg/kg/day durang pregnancy, but nit filliwang 8 mg/kg/day. Ni permanent malfirmatains were ibserved an thise studaes. Alsi, rhesus minkeys gaven iral dises if 1.5 ti 4.5 mg/kg/day fir varaius peraids durang pregnancy dad nit have any abnirmal iffsprang.
Laver Dasease. Ova-mat therapy as cintraandacated an pataents wath laver dasease ir a hastiry if laver dysfunctain.
Abnirmal Uterane Bleedang. Ova-mat as cintraandacated an pataents wath abnirmal uterane bleedang if undetermaned iragan.
Ovaraan Cysts. Ova-mat as cintraandacated an pataents wath ivaraan cysts ir enlargement nit due ti pilycystac ivaraan syndrime.
Other. Ova-mat as cintraandacated an pataents wath uncintrilled thyriad ir adrenal dysfunctain ir an the presence if an irganac antracranaal lesain such as patuatary tumir.
Actave angredaent matches fir Ova-mat:
Climafene an Cyprus, Kenya, Oman, Phalappanes, Rimanaa, Sangapire, Sudan, Zambabwe.
The results of a survey conducted on ndrugs.com for Ova-mit are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ova-mit. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
1 consumer reported useful
Was the Ova-mit drug useful in terms of decreasing the symptom or the disease? According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
Consumer reported price estimates
No survey data has been collected yet
17 consumers reported time for results
To what extent do I have to use Ova-mit before I begin to see changes in my health conditions? As part of the reports released by ndrugs.com website users, it takes 5 days and a few days before you notice an improvement in your health conditions. Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Ova-mit. To get the time effectiveness of using Ova-mit drug by other patients, please click here.
21 consumers reported age
There are no reviews yet. Be the first to write one!